Clinical Trial Update: Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation [Phase 2]

View source ↗

Summary

This is a Phase 2 trial evaluating plerixafor (AMD3100) to mobilize peripheral blood cells in multiple myeloma patients for collection and transplantation. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Plerixafor (Mozobil) (plerixafor)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2010-10-21